- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12. | Kairos Pharma Ltd.: Kairos Pharma to Participate in The Microcap Conference in January 2025 | 210 | ACCESSWIRE | LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025... ► Artikel lesen | |
| 13.12. | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings | ||
| 25.11. | Finanzvorstand von Kairos Pharma, Doug Samuelson, erwirbt Stammaktien im Wert von 3.750 US-Dollar | 1 | Investing.com Deutsch | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.11. | Kairos Pharma approved to dual list on Upstream | 2 | Seeking Alpha | ||
| 19.11. | Kairos Pharma, Ltd.: Kairos Pharma Approved to Dual List on Upstream | 2 | GlobeNewswire (USA) | ||
| 19.11. | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 22.10. | Kairos Pharma, Ltd.: Kairos Pharma to Present at the LD Micro Main Event XVII | 1 | GlobeNewswire (USA) | ||
| 09.10. | Kairos Pharma, Ltd.: Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 04.10. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.09. | Kairos Pharma, LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.09. | Prevail Partners and Prevail InfoWorks Enter Into Strategic Investment and Clinical Alliance With Kairos Pharma, Ltd. | 272 | ACCESSWIRE | PHILADELPHIA, PA / ACCESSWIRE / September 25, 2024 / Prevail Partners LLC ("Prevail Partners") and Prevail InfoWorks Inc. ("Prevail InfoWorks") announce that they have entered into a strategic relationship... ► Artikel lesen | |
| 24.09. | Kairos Pharma, Ltd.: Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients | 1 | GlobeNewswire (USA) | ||
| 24.09. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Kairos Pharma, Ltd.: Kairos Pharma Closing of $6.2 Million Initial Public Offering | 154 | GlobeNewswire (Europe) | LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. ("Kairos Pharma" or the "Company") (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics... ► Artikel lesen | |
| 17.09. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.09. | Micro-cap cancer biotech Kairos Pharma prices IPO at $4 | 4 | Renaissance Capital | ||
| 16.09. | Kairos Pharma opens at $4, IPO priced at $4 | 2 | Investing.com | ||
| 16.09. | Kairos Pharma Prices $6.2 Mln IPO At $4 Per Share | 521 | AFX News | WASHINGTON (dpa-AFX) - Kairos Pharma, Ltd. Monday announced the pricing of its initial public offering of 1.55 million shares of common stock at $4.00 per share. The clinical stage company has... ► Artikel lesen | |
| 16.09. | Kairos Pharma Prices 1.55M Share IPO at $4/sh | 2 | Investing.com |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 7,270 | +4,01 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| TEMPUS AI | 34,650 | -0,74 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| SUMMIT THERAPEUTICS | 18,940 | +1,45 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| ADMA BIOLOGICS | 17,390 | -1,86 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| EDGEWISE THERAPEUTICS | 29,660 | -1,07 % | Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains | ||
| 180 LIFE SCIENCES | 2,740 | +46,52 % | 180 Life Sciences Corp. - S-1/A, General form for registration of securities | ||
| JANUX THERAPEUTICS | 56,13 | -1,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,810 | -1,50 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,450 | +2,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies | ||
| ARCUTIS BIOTHERAPEUTICS | 14,980 | +0,07 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| NUVALENT | 82,83 | -1,22 % | Nuvalent-CEO Porter James Richard verkauft Aktien im Wert von 2,34 Millionen US-Dollar | ||
| ARCELLX | 77,10 | +0,40 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| ALPHA TEKNOVA | 8,615 | +12,17 % | Alpha Teknova Stock Hits 52-Week High at $8.93 Amid Growth Surge | ||
| NEUMORA THERAPEUTICS | 10,745 | -3,37 % | Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3% - Should You Sell? | ||
| HUMACYTE | 4,525 | -2,69 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen |
KAIROS PHARMA LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,700 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.
